Ann: First-in-human Study Progress Update, page-64

It would be fair to assume that today's announcement has certainly de-risked our investment. No safety issues to date and a likely probability we wont see an issue even when we reach the full cohort. Never was much of a risk anyway, injectionable iron-oxide nanoparticles have been widely used in humans for a while now ( ours is different only in regard the antigen coating to target HER cancer cells). The observation that our nanoparticles have successfully reached ( attached to?) the lymph nodes target is the main takeaway point. Thats a huge re-risk for us